Instituto de Hematología e InmunologíaInstituto de Hematología e InmunologíaInstituto de Hematología e InmunologíaInstituto de Hematología e InmunologíaInstituto de Hematología e InmunologíaIHI
jueves, 18 de abril de 2024
 
Titulares


Cell therapy in Cuba: introduction, development and perspectives.

Authors: Dr. José A. Galván Cabrera,1 Dr. Porfirio Hernández Ramírez,1  Dr. Aymara Baganet Cobas,1 Dr. Consuelo Macías Abraham,1 Dr. Norma Fernández Delgado,1 Dr. Elvira Dorticós Balea,1 BSc. Tania González Suárez,1 BSc. Ana I. González Iglesias,1 Dr. Rosa M. Lam-Díaz,1  BSc.  Berta B. Socarrás Ferrer,1 BSc.  Lázaro O. del Valle Pérez,1 Dr. Yoel de León Delgado,2 MSc. Alex Miranda Rodriguez.2

1 Instituto de Hematología e Inmunología (IHI), La Habana Cuba.
2 Centro de Inmunología Molecular (CIM), La Habana Cuba.

This presentation is about the uses of adult stem cell for the cellular therapy in Cuba. The basic and clinical researches carried out during past years on the stem cells and its therapeutic possibilities are at present times, one of the most interesting subjects of the contemporaneous medicine. There are advances in the study and application of adult stem cells showing remarkable advantages on the embryonic ones, since its handling is more simple, economic and they are obtained from the own subject to be treated. For the introduction in Cuba of the regenerative cellular therapy in the Institute of Hematology and Immunology the cellular sources selected were the adult stem cells derived from bone marrow and the mobilized ones to the peripheral blood. To make easy the expansion of treatment to other hospitals, in our center, we standardized a technique for the mobilization of the hematopoietic stem cells to peripheral blood using a granulocyte colony-stimulating factor (Filgrastim, of national production) developing a simple, economic and more tolerable method for patients. In this way, the cellular therapy has been expanded to 14 of 15 Cuban provinces and until June 2014, 6195 cases with autologous adult stem cells transplant have been treated, from which the 50,4% (3126 cases) to correspond to patients presenting with Angiology diseases with a significant reduction of major amputations; 44,4% (2747 cases) with Orthopedic diseases and 5,2% (322 cases) with others diseases. The results obtained until now may be considered as a new achievement of revolutionary science and of our national health systems and of science and technique. The method used is an economic and feasible procedure for the institutions of the developing countries with scarce resources.

 
: Editor Principal, Instituto de Hematología e Inmunología | Instituto de Hematología e Inmunología, MINSAP | San Francisco y Perla. Altahabana, Boyeros, Ciudad de La Habana, 10800, Cuba | Teléfs.: (537) 6438268, (537) 6438695 y telefax: (537) 6442334, Horario de atención: 8:00 a.m a 4:00 p.m., de Lunes a Viernes